Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Whitehawk Therapeutics, Inc. Director's Dealing 2017

Dec 18, 2017

34276_dirs_2017-12-18_54e520aa-d1a4-4d20-85d1-e272b6d71a91.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Aerpio Pharmaceuticals, Inc. (ARPO)
CIK: 0001422142
Period of Report: 2017-12-14

Reporting Person: HOFFMAN STEPHEN J (Director, Chief Executive Officer)

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2017-12-14 Stock Option (Right to Buy) $5.50 A 586012 Acquired 2027-12-01 Common Stock (586012) Direct

Footnotes

F1: Options exercisable as to 1/4th on the first anniversary of the grant date and an additional 1/48th monthly thereafter until the fourth anniversary of the grant date.